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Abstract
Background: The selection of appropriate outcomes or domains is crucial when designing clinical trials, to appreciate
the effects of different interventions, pool results, and make valid comparisons between trials. If the findings are to
influence policy and practice, then the chosen outcomes need to be relevant and important to key stakeholders,
including patients and the public, healthcare professionals and others making decisions about health care. There is a
growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials.
Recent reviews of the measurement properties of patient-reported outcome measures for shoulder disorders
revealed a large selection of diverse measures, many with questionable validity, reliability, and responsiveness.
These issues could be addressed through the development and use of an agreed standardized collection of outcomes,
known as a core outcome set (COS), which should be measured and reported in all trials of shoulder disorders. The
purpose of the present project is to develop and disseminate a COS for clinical trials in shoulder disorders.
Methods/Design: The methods for the COS development will include 3 phases: (1) a comprehensive review of the
core domains used in shoulder disorder trials; (2) an international Delphi study involving relevant stakeholders (patients,
clinicians, scientists) to define which domains should be core; and (3) an international focus group informed by the
evidence identified in phases 1 and 2, to determine which measurement instruments best measure the core domains
and identification of any evidence gaps that require further empiric evidence.
Discussion: The aim of the current proposal is to convene several meetings of international experts and patients to
develop a COS for clinical trials of shoulder disorders and to develop an implementation strategy to ensure
rapid uptake of the core set of outcomes in clinical trials. There would be an expectation that the core set of
outcomes would always be collected and reported, but it would not preclude use of additional outcomes in
a particular trial.
Keywords: Outcome measures, Core outcome set, Clinical trials, Shoulder, Rotator cuff, Adhesive capsulitis,
Osteoarthritis, Pain
Background
The shoulder is one of the more complex joints in the hu-
man body and a wide variety of conditions can affect the
structures of the shoulder. The most common cause of
shoulder pain is rotator cuff disease, which, in one primary
care study, accounted for 85% of all shoulder pain
presentations [1]. Adhesive capsulitis is also a common
cause in middle-aged individuals, while osteoarthritis is
becoming increasingly prevalent in older people. Shoulder-
related disorders account for substantial medical, economic,
and social costs [2, 3]. In 2000, the direct costs for the treat-
ment of shoulder dysfunction in the USA totaled US$7
billion [4, 5]. Nearly 20 million Americans reported shoul-
der pain in 2005 alone, establishing shoulder pain third only
to knee and back pain [6]. A systematic review showed that
the estimated prevalence of shoulder pain in the general
population varies greatly among studies, with a lifetime
reported prevalence ranging from 7% to 67% [7]. With the
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aging “baby boomer” generation, we can expect the preva-
lence of shoulder disorders to increase significantly over the
next two decades [6].
Shoulder disorders are associated with acute or chronic
pain that is often disabling; some disorders also result in
weakness and dysfunction of the upper extremity [8].
They have a substantial effect on quality of life, including
altered sleep patterns, and adversely impact work and re-
creation [9]. For example, up to 30% of workers diagnosed
with a new episode of shoulder pain take sick leave be-
cause of the shoulder disorder [10]. Also, patient-reported
outcomes (PROs) research suggests that shoulder disor-
ders may compromise an individual’s health status similar
to major medical diseases, including congestive heart fail-
ure, acute myocardial infarction, diabetes mellitus, and de-
pression [11, 12].
There are many hundreds of controlled clinical trials
for shoulder disorders and some evidence suggests that
these studies tend to use a heterogeneous array of out-
come measures [13–17]. For example, four recent
Cochrane reviews, limited to randomized and quasi-
randomized trials investigating manual therapy and exer-
cise or electrotherapy for adhesive capsulitis or rotator
cuff disease, included 32, 19, 60, and 47 trials, respect-
ively [13–16]. A review of the included trials found that
trialists included a measure of pain in 87%, function in
72%, range of motion in 67%, adverse events in 27%,
patient-reported treatment success in 24%, strength in
18%, health-related quality of life in 18%, work disability
in 4%, and referral for surgery in 2% [17]. Rotator cuff
disease trials more commonly included a measure of
strength (26% versus 2% for adhesive capsulitis), whereas
adhesive capsulitis trials more commonly included a
range of motion measure (82% versus 58% in rotator cuff
disease trials). Also, the measurement tools used to as-
sess these domains varied widely. For example, there
were 35 different outcome measures for pain. Further-
more, between 1973 and 2014 there was a marked rise
in inclusion of a measure of function accompanied by a
marked decline in use of a measure of range of movement.
It has been suggested that few outcome measures for
shoulder disorders possess acceptable measurement
properties (e.g., [18–21]). To be of use for clinical trials
and patient care, health status measurement instruments
must be valid, reliable, and responsive [22, 23]. A valid
tool measures what it proposes to measure and must ful-
fill requirements for face, content, construct, and/or
criterion validity. A reliable instrument measures some
phenomenon in a predictable manner (repeatability or
reproducibility), whether it is self-reported (test-retest
reliability) or is measured by someone else (intra-rater
and inter-rater reliability). Finally, a responsive measure
is able to detect clinically important change in the
underlying construct over time, even if the changes are
small, and crucially for clinical trials, must be able to de-
tect clinically important differences in treatment effect
[22, 23]. There are several checklists and recommenda-
tions on how to assess the full array of psychometric
properties across health-status measurement instru-
ments (e.g., [24–27]). Until recently, there was a paucity
of studies that have comprehensively assessed outcome
measures used for shoulder disorders, or identified
where there are gaps in empiric data to guide further
research efforts.
A systematic review of PRO measures used in studies of
rotator cuff disease identified 73 separate citations for 16
distinct PRO measures [19] and performed a comprehen-
sive assessment of their methodological quality (using the
consensus-based standards for the selection of health status
measurement instruments (COSMIN) checklist) [24, 25],
psychometric properties (using criteria proposed by Terwee
et al. [26]), and overall evidence using accepted methods
[27]. Outcomes had empiric data supporting an average of
only 50% of recommended measurement properties. Tools
such as The Western Ontario Rotator Cuff (WORC) Index,
Disability of the Arm, Shoulder and Hand measures
(DASH), Shoulder Pain and Disability Index (SPADI), and
Simple Shoulder Test (SST) had good evidence in support
of their measurement properties, while there were concerns
about other tools relating to internal consistency, reliability,
measurement error, hypothesis testing, and responsiveness.
Another recent systematic review assessed the psycho-
metric properties of shoulder-specific PRO measures
using a different tool - Evaluating Measures of Patient
Reported Outcomes (EMPRO) [28]. It identified 11 in-
struments assessed across 112 studies. The American
Shoulder and Elbow Surgeons (ASES) shoulder assess-
ment, SST, and Oxford Shoulder Score (OSS) were
found to have low administration burden and the best
overall scores for validity, reliability, and responsiveness,
while the Flexilevel Scale of Shoulder Function, SPADI,
and the Dutch Shoulder Disability Questionnaire had
some acceptable properties, but several required further
evaluation.
A third systematic review used the COSMIN methodo-
logical quality checklist to assess questionnaires used to
evaluate interventions for rotator cuff disease, including
surgery [29]. Sixteen studies evaluating two instruments,
the WORC and the Rotator Cuff Quality-of-Life (RC-QOL)
measure, were identified. Both tools were found to have ad-
equate construct validity, reliability, responsiveness, internal
consistency, and translation but additional methodological
aspects - including measurement error, content, structural,
cross-cultural and criterion validity, and interpretability -
needed further evaluation. A fourth paper assessed the psy-
chometric properties (using criteria proposed by Terwee et
al. [26]) of four commonly used shoulder outcome instru-
ments - the ASES, the Constant-Murley score, the DASH
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and the OSS - and reported that each of them had limited
evidence to support their use in shoulder trauma popula-
tions [30]. Last, a fifth systematic review of measurement
properties of self-administered PRO measures in patients
with nonspecific shoulder pain and activity limitations
found that none of the seven PRO measures had strong
positive evidence for all properties but that the SPADI was
the best and was recommended for use in these patients
[31].
The lack of uniformity in outcome measurement
across trials limits our ability to compare findings be-
tween studies or to pool data for meta-analyses. Selective
outcome reporting (i.e., selective reporting of favorable
or statistically significant outcomes) can also bias the
results of systematic reviews [32]. In an effort to reduce
heterogeneity in outcomes measured across clinical tri-
als, the development of core outcome sets (COSs) for
specific health conditions has been recommended [33].
A COS is defined as an agreed minimum selection of
outcomes that should be measured and reported in all
clinical trials for a particular health condition [34].
There would be an expectation that the core set of out-
comes would always be collected and reported, but it
would not preclude use of additional outcomes in a
particular trial. A COS would increase the reporting of
important outcomes, reduce the risk of selective out-
come reporting, and increase the feasibility of conduct-
ing meta-analyses on such topics [34, 35]. We searched
the COMET database and no COS was identified for
this area.
The aim of this project is to develop a COS for clinical
trials of shoulder disorders. The Core Outcome
Measures in Effectiveness Trials (COMET) [34] and the
Outcome Measures in Rheumatology (OMERACT) [36]
initiatives provide methodological guidance, including a
stepwise approach, for the development of a COS [37, 38].
The long-term goal of this work is to ensure the use of an
internationally agreed COS based upon the best available
evidence, for all trials of shoulder disorders. This will
greatly improve our ability to interpret and compare the
findings of different trials and synthesize the evidence in
meta-analyses, and will also address the issue of selective
outcome reporting.
Methods
Definitions of key concepts and terms used in this
protocol follow those recently outlined by the OMER-
ACT initiative [37] and are presented in Table 1 [39].
This protocol followed recommendations in the SPIRIT
checklist (see Additional file 1).
Establishing a Steering Committee
An International Steering Committee was formed to ini-
tiate and support the development of this COS and the
Special Interest Group (SIG) at the OMERACT 16 meet-
ing, 11–14 May 2106 in Whistler, BC, Canada. The
steering committee includes three individuals with ex-
pertise in PRO measures and COS development, includ-
ing Dr. Rachelle Buchbinder (RB; Australia), Dr. Joel
Table 1 Definitions of concepts [39]
Concept Definition
Health condition A situation of impaired health
Health intervention An activity performed by, for, with, or on behalf of a client(s) the purpose of which is to improve individual or
population health, to alter or diagnose the course of a health condition, or to improve functioning
Core area An aspect of health or a health condition that needs to be measured to appropriately assess the effects of a health
intervention (core areas are broad concepts consisting of a number of more specific concepts called domains)
Domain or subdomain Component of core area: a concept to be measured, a further specification of an aspect of health, categorized within
a core area
Outcome Any identified result in a (sub)domain arising from exposure to a causal factor or a health intervention
Measurement instrument A tool to measure a quality or quantity of a variable, in this context a (sub)domain or a contextual factor
Outcome measurement
instrument
A measurement instrument chosen to assess outcome(s)
Core domain set For study of health interventions, the minimum set of domains and subdomains necessary to adequately cover all
core areas (fully measure all relevant concepts of a specific health condition within a specified scope); it describes
what to measure
Core outcome
measurement set
The minimum set of outcome measurement instruments that must be administered in each intervention study of a
certain health condition within a specified setting to adequately cover a corresponding core domain set; it describes
how to measure
Scope The set of factors that describes the studies and circumstances to which the core outcome set will apply. This is
determined by the study questions and includes the health condition(s), target population, interventions, and so forth
Contextual factor Variable that is not an outcome of the study, but needs to be recognized (and measured) to understand the study
results. This includes potential confounders and effect modifiers
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Gagnier (JG; USA) and Dr. Arianne Verhagen (AV; The
Netherlands). We also included two fellows, in line with
OMERACT recommendations. The project is led by the
Project Team (JG, RB), who will coordinate the day-to-
day management of the project and meetings. Members
of the steering committee and fellows were contacted by
email and telephone regarding key decisions.
Scope of the core outcome set
The COS we develop will apply to measuring efficacy or
effectiveness of any health interventions in clinical trials
for patients with shoulder disorders. For this COS,
shoulder disorders include rotator cuff disorders, adhe-
sive capsulitis, osteoarthritis, instability, dislocation of
the shoulder, proximal humeral fractures, and nonspe-
cific shoulder pain. It is expected that all domains of this
COS should be included in all clinical trials for shoulder
disorders. However, in agreement with the COMET def-
inition [34], this does not imply that primary outcomes
of a clinical trial should always be those of the developed
COS or that outcome measures should be restricted to
the domains of the COS (they can include other do-
mains of relevance to the specific research question).
Stakeholder involvement
It is routinely recommended that an array of stakeholders
be involved in the development of a COS, including scien-
tists/researchers, healthcare providers (e.g., primary care cli-
nicians (including primary care physicians and physical
therapists), specialists (e.g., rheumatologists and ortho-
paedic surgeons, nurses, physician assistants, etc.), patients,
government agencies (e.g., funding bodies, healthcare regu-
lators), payers (e.g., healthcare insurance companies, federal
health care coverage bodies), and industry representatives
[34, 36, 40]. For this COS, the project team will include the
following stakeholders:
1. Healthcare scientists/researchers: individuals
working in fields of clinical research for shoulder
disorders (e.g., orthopaedics, physiotherapy,
rheumatology, physical medicine, and rehabilitation),
and clinical trial or clinimetric methodologists, or
biostatisticians. In addition, any scientists/
researchers included as stakeholders in this project
will be authors of peer-reviewed scientific articles
related to clinical research for shoulder disorders.
Healthcare scientists/researchers may also be
healthcare providers.
2. Healthcare providers: healthcare professionals
from different disciplines (e.g., primary care
physicians, physical therapists, rheumatologists,
orthopaedic surgeons, nurses, physician assistants),
who have clinical experience in the management
of patients with shoulder disorders. Healthcare
providers may also be healthcare scientists/
researchers.
3. Patients: individuals who currently have or have had
a shoulder disorder(s), and who sought care for the
condition. Some previous research has illustrated
that it is limiting not to include patients in the
development of a COS [34]. Patients have the
perspective of living with the health condition and
this may substantially differ from the perspective of
researchers and providers.
A conceptual framework
An elucidation of a comprehensive framework of health
care is necessary when developing a COS. That is, a
COS that focuses on only a few of the components of
“health” might be considered narrow. The OMERACT
initiative has recently developed a framework that in-
cludes key aspects of a health condition to ensure com-
prehensiveness in COSs (Fig. 1) [38]. This conceptual
framework is subdivided into core areas that encompass
the complete content of what is measurable in a clinical
trial. It includes three core areas that encompass the
“impact of health condition” (“death”, “life impact”’, and
“resource use/economic impact”) and that describe
“pathophysiological manifestations”. Table 2 describes
each of these core areas and was adopted from a re-
cently published protocol on the development of COS
for nonspecific low back pain [39]. Overall, OMERACT
recommends the inclusion of at least one domain from
each core area in every COS [37, 38]. The OMERACT
Filter 2.0 framework will be used by the Steering Com-
mittee to help the development of a list of potential core
domains and for discussion during the Delphi study.
Research methods
This project will consist of three phases. Phase 1 will
generate a list of the core domains. This will include a
review of the domains (or subdomains) assessed, or pro-
posed to be assessed, in outcome measures used in clin-
ical research of patients with shoulder disorders. Phase 2
will complete an international Delphi study involving
relevant stakeholders (patients, clinicians, researchers/
scientists) to define which domains identified in phase 1
should be core. During phase 3 an international focus
group informed by the evidence identified in phases 1
and 2 will determine which measurement instruments
best measure the core domains and identify any evi-
dence gaps that require further empiric evidence. Phase
3 took place at the OMERACT 2016 meeting. These
methods have been used in the development of other
COSs (e.g., [39]) and are recommended for use by the
OMERACT [37, 38] and COMET initiatives [41]. Fi-
nally, we will disseminate our findings to relevant
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research and scientific groups through publications, con-
ference workshops, meetings and position papers with
relevant organizations.
Phase 1: generation of a list of potential core domains
We will perform a review of health measurement do-
mains and outcome tools used in trials involving people
with shoulder disorders. All included trials from relevant
Cochrane reviews published in the Cochrane Library will
be reviewed. All reviews that synthesize the evidence for
the efficacy or effectiveness of any interventions (other
than physical therapy) for one the following shoulder
conditions will be considered: rotator cuff disease
including rotator cuff tears, adhesive capsulitis, osteoarth-
ritis instability, dislocation of the shoulder, proximal
humeral fractures and nonspecific shoulder pain. We will
use the search strategy for shoulder pain systematic re-
views already developed by the Cochrane Musculoskeletal
Group. We will also search for and identify randomized
controlled trials published within the prior 10 years in
PubMed. Two reviewers will assess all studies for
inclusion and will extract the domains and outcome tools
used in all identified trials, and additional trial characteris-
tics. These domains will then be classified into the core
areas described in the OMERACT framework (Fig. 1).
Next, we will invite feedback on these domains
from members of the Steering Committee, who will
be asked to provide critical comments on each do-
main. The members will also be asked to indicate if
important potential core domains are missing or if
certain domains are too broad or should be aggre-
gated. The project team will then finalize the list of
potential core domains that will be used during the
Delphi study.
Phase 2: Delphi consensus process
An international Delphi process will be used to reach
consensus on the core domains, similar to the process
used in another project updating the COS for back pain
trials [39]. This method is used to gain consensus among
a group of experts or informed respondents that consti-
tute the Delphi panel [34]. The respondents anonym-
ously complete sequential questionnaires that constitute
Table 2 Description of core area outlined in OMERACT Filter 2.0 [33–35]
Core Area Description
Death Includes possible specifications of death, such as generic or disease-specific (all-cause versus
disease-specific mortality),
and intervention-specific (for example, death due to surgery)
Life impact Can include domains such as activity and participation and domains within the concept of
health-related quality of life such as functional status, general health perceptions, and overall quality of life
Resource use/economic impact Economic impact of health conditions on both society and the individual
Pathophysiological
manifestations
This core area is meant to assess whether or not the effect of the intervention specifically targets the
pathophysiology of the health condition and may include psychosocial manifestations. Example domains
include: body function, reversible manifestations (including modifiable risk factors and actual manifestations
of ill health), and irreversible manifestations (including non-modifiable risk factors and damage). This can
also include biomarkers and surrogate outcomes
Fig. 1 Conceptual framework of core areas for outcome measurement in health intervention studies [38]. ICF International Classification of
Functioning, Disability and Health
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consecutive Delphi rounds. After each round, the group
responses are fed back to the panelists who can recon-
sider their views based on the report of the group views
[34]. The Delphi method avoids situations in which the
group is dominated by the views of a few prominent
personalities.
Selection of panel members
On the basis of the findings and methods of related re-
search [39], a minimum of 80 participants will be re-
quired in each round of the Delphi. With an expected
minimum response rate of 40% [39], at least 200 people
will be invited to participate in the Delphi rounds, in-
cluding an equal number, approximately 67, from each
of these three groups: researchers, healthcare providers
and patients.
First, a Web of Science search will be performed to
compile a list of researchers who have published on one
or more shoulder disorders over the last 10+ years
(2004–2015). We will also identify and include first and
senior authors of a shoulder pain clinical trial or one
systematic review.
To identify healthcare providers, Steering Committee
members and researchers identified above will be asked
to provide the names of clinicians from different disci-
plines who have experience in managing patients with
shoulder disorders.
Next, we will ask Steering Committee members and
researchers identified above who have direct contact
with patients with shoulder disorders to identify suit-
able patients to invite to participate. Inclusion criteria
for patient participants are as follows: present or past
history of shoulder disorders, seeing a healthcare pro-
vider for their shoulder pain, and understanding of
written English. Patient recruitment should ensure
representation across shoulder disorders, so that opin-
ions may represent a wide selection of patient groups,
improving the generalizability of our findings. All
patient participants, up to a maximum of 70, will be
compensated monetarily, US$25, for completion of
each voting round, for a total of US$50 each if both
rounds are completed.
The final list of all selected panelists will be kept confi-
dential and known only to the project team members.
Overview of the Delphi procedure
All panel members will be invited to participate in two
Delphi rounds unless they explicitly indicate at some
point during the study that they do not wish to receive
further invitations. A third round will be conducted only
if agreement cannot be reached after two rounds. From
the results of phase 1 the project team will develop
questions, design the complete Delphi questionnaire,
send invitations and reminders to panel members,
analyze responses, and formulate feedback reports. We
will pilot test the Delphi questionnaires with the Steering
Committee members. The online software SurveyMon-
key (SurveyMonkey, Palo Alto, CA, USA) will be used to
complete the Delphi study. The questionnaire for each
round will be available for 4 weeks, with a reminder sent
1 week after the initial invitation [40].
Delphi round one
Participants will be given information about the objec-
tives of the study and the questionnaire. First, they will
be asked to respond to several demographic questions,
including educational and professional backgrounds,
country of origin, experience with clinical research rele-
vant to shoulder disorders, and whether they were in-
vited to participate as patients. Next, participants will
be asked to rate the importance of the core domains
identified in phase 1. Participants will be specifically
asked to indicate the importance of each domain to be
included in this core domain set; response options will
include “Yes”, “No”, and “Unsure/I do not know”. Each
question will include an option for comments, and par-
ticipants will be encouraged to provide a rationale for
their ratings and suggest modifications of definitions or
wording of the domains. Furthermore, participants will
be asked to indicate if there is any overlap between
domains, to suggest whether some domains might be
aggregated, and to suggest potential core domains not
included in the list.
We will calculate frequencies for the response options
on the importance of each domain across all partici-
pants and for each type of panelist (i.e., patients, clini-
cians, scientists, clinician-scientists). Responses to open
questions will be reviewed and organized thematically
to evaluate if significant arguments are against the
overall trend in frequencies. Patient responses will be
analyzed separately to determine if they differ from the
responses of the other panelists. Those domains to
which more than two thirds (67%) of the responders
choose the response option “Yes” will be included in
the list of core domains. Those domains for which there
is substantial disagreement across the groups of panel-
ists, or a high percentage (>67%) of “No” responses, will
be eliminated from the core set. Those domains with
greater than one third but less than two thirds “Ye” re-
sponses or some disagreement across the groups of
panelists will be reconsidered for voting in round 2.
The project team will consider the suggestions for the
aggregation of certain domains and the strength of the
arguments by deliberation and discussion. Suggested
missing core domains will be added to the list for the
next Delphi round. All survey findings will be organized
into a feedback report. The Delphi survey questions will
be modified to reflect these findings for use in round 2.
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Delphi round two
The feedback report will be emailed to all Delphi partici-
pants together with the second round of the survey. Par-
ticipants will be asked to comment on the feedback
report to inform us of any overwhelming and convincing
arguments against any of the survey or domain changes.
As in round 1, participants will be asked to complete the
second round of questions. Specifically, they will be
asked to indicate the importance of each domain to be
included in this core domain set; response options will
include “Yes”, “No”, and “Unsure/I do not know”.
We will calculate frequencies for the response options
on the importance of each domain across all participants
and for each group of panelists. Responses to open ques-
tions will be reviewed to evaluate if significant argu-
ments given are against the overall trend in frequencies.
Patient responses will be analyzed separately to deter-
mine if they differ from the other panelist responses. All
survey findings will be organized into a feedback report.
Results will be discussed by the project team, who will
assess whether there are substantial arguments against
the overall consensus, or to the changes in the survey
made from round one and the list of core domains. Fi-
nally, if there are clear discrepancies between stake-
holder groups or controversial arguments, the results
will be presented to the Steering Committee to make
final decisions and these finding will be presented during
the meetings held during phase 3 of this project.
Phase 3: focus groups informed by the evidence
identified in phases 1 and 2
Pre-OMERACT meeting
A pre-OMERACT 16 meeting will be held for all stake-
holders with an interest in a COS for shoulder disorders,
who will also be invited to participate in the SIG for
shoulder disorders at OMERACT 16. We expect that at
a minimum, the pre-OMERACT meeting will be attended
by the Steering Committee, two fellows, two patient par-
ticipants, and as many scientists and researchers as pos-
sible. All travel, lodging and food-related expenses of the
pre-OMERACT focus group attendees will be covered,
and each patient participant will receive a US$500 gift.
The purpose of this meeting will be to present the re-
sults of the Delphi study and obtain final consensus on
the included domains in the shoulder disorder COS. We
will present an overview of the rationale for the COS, its
purpose, and the process that we have undertaken to
develop it. We will then present the consensus on the
core domains that should be included.
However, because this process will be driven by
evidence-based reviews of what is currently measured in
clinical trials, an important aim of the meeting will be to
ensure that all domains of importance to the relevant
stakeholders have been captured. Therefore, a nominal
group process will be conducted to elicit opinion from
all attendees and ensure that the full breadth of the bur-
den experienced by patients and observed by experts in
the COS domains has been captured. This work will be
performed in a fashion similar to that used to develop
models for low back pain [42] and osteoarthritis [43]. In
both instances, this process identified important as-
pects of personal burden that are not routinely con-
sidered and might be overlooked in a COS [42, 44].
We will also consider whether specific additional do-
mains (and measurement tools of those domains) may
be needed for different shoulder disorders (e.g., a
measure of strength for rotator cuff disorders and a
measure of range of motion for adhesive capsulitis), if
these are not part of the core set.
Special Interest Group (SIG) meeting at OMERACT 16
At the SIG meeting of the shoulder group at OMERACT
16 we will present our progress to date to all attendees,
including the proposed core domain set as determined
from the international consensus study and the pre-
OMERACT meeting. Attendees will include two patient
stakeholders. We will then invite comments and discus-
sion to help refine the core domain set. This will be an
important forum to obtain valuable feedback and ensure
that the final COS domains receive OMERACT endorse-
ment. We will proceed until the attendees are in agree-
ment with the COS domains, which will be confirmed
by a formal vote for or against the domain set.
Selection of instruments for COS domains
The Steering Committee and fellows will select outcome
measurement instruments that propose to measure the
domains identified above. Only instruments that have
empirical evidence to support their validity, reliability
and responsiveness will be considered. To identify em-
pirical evidence we will search for systematic reviews of
instrument properties (e.g., [19]). Where no systematic
reviews are available, literature searches will be per-
formed and each instrument assessed using accepted
methods [19–27]. All findings will then be organized to
arrive at a recommended core outcome measurement
set. Several scientists will be consulted for their advice
and comments on our choice of instruments.
Dissemination of the COS recommendations
To hasten the uptake of our findings, we have devel-
oped a dissemination plan that considers the intended
audience and the best channels of delivery to effect
successful implementation of the COS recommenda-
tions. In the first instance we will publish our proto-
col for the formation of the COS. We will then
proceed to publish our findings summarizing the core
set of domains that should be included in all shoulder
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trials and subsequently submit for publication the re-
sults for which outcome measurement instruments
should be used to measure each domain. Our recom-
mendations will be updated on the basis of any fur-
ther data that might become available in future peer-
reviewed publications. Our findings will also be pre-
sented at relevant scientific meetings across different
disciplines and outcome-measurement-specific venues
(e.g., orthopaedics: American Association of Orthopaedic
Surgeons (AAOS), Orthopaedic Research Society (ORS)
annual meeting, and other orthopaedic meetings inter-
nationally that are attended by our working group partici-
pants; rheumatology: American College Rheumatology
(ACR), the European League Against Rheumatism
(EULAR), and Australian Rheumatology Association
(ARA) meetings; physical therapy: American Physical
Therapy Association (APTA) meeting; COMET annual
meeting). Furthermore, we plan to give workshops at sev-
eral of these same scientific meetings on COS creation for
musculoskeletal conditions. We will also publish the rec-
ommended COS in the COMET database, where we have
already registered two preliminary projects [17, 45].
Importantly we will also evaluate the success of our
dissemination strategy on the basis of predetermined
short-term and long-term desired outcomes. Examples
of the former include the number of times publications
that describe the COS are accessed, downloaded, or
cited (via citation tracker); examples of long-term de-
sired outcomes would include evidence of use in clinical
trials according to trial registry review, and a future re-
view to compare outcomes measured before and after
publication of the COS.
Discussion
The information provided in this protocol is consistent
with the information required in the methods section
of a full report of a COS, as set out in the COS-STAR
guidance [46]. The expected outcome of our project is
a core outcome set for use in all clinical trials of shoul-
der disorders. Use of this core set will markedly
improve the value of clinical trials of interventions for
shoulder disorders and reduce research waste. It will
improve our ability to interpret clinical findings, com-
pare results across different trials and synthesize the
best available evidence by meta-analysis. The core out-
come set will also reduce the risk of selective outcome
reporting. Inclusion of patients, clinicians, and re-
searchers/scientists in the process will ensure that all
relevant stakeholder perspectives are captured. Inclu-
sion of recognized international experts who are ac-
tively involved in clinical trials in this area in the COS
development process will hasten the uptake of the core
set into future trials.
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